AtriCure, Inc. develops surgical and minimally invasive technologies for atrial fibrillation, left atrial appendage management and post-operative pain management. Company updates commonly cover quarterly and annual financial results, U.S. and international revenue trends, product adoption for AtriClip, cryoSPHERE, EnCompass and related device families, and clinical programs tied to Afib treatment and pain-blocking cryoablation.
Its disclosed product portfolio includes the FDA-approved Isolator Synergy Ablation System for persistent Afib, AtriClip Left Atrial Appendage Exclusion System products, Hybrid AF Therapy, and cryoICE cryoSPHERE and cryoXT probes for temporary peripheral nerve ablation.
AtriCure, Inc. (NASDAQ: ATRC) has announced its participation in the 34th Annual Piper Sandler Healthcare Conference. The company is set to present on November 30, 2022, at 9:30 a.m. Eastern Time. A live audio webcast can be accessed via the Investors section on AtriCure's website. AtriCure specializes in surgical treatments for atrial fibrillation (Afib) and related conditions, providing innovative technologies including the FDA-approved Isolator® Synergy™ Ablation System and AtriClip® devices for left atrial appendage management.
AtriCure, Inc. (Nasdaq: ATRC) reported third quarter 2022 revenue of $83.2 million, an 18.1% increase from the previous year. U.S. revenue rose to $69.8 million, up 21.3%, driven by strong sales of the cryoSPHERE® probe and AtriClip® Flex·V® device. International revenue grew by 4.2% to $13.4 million. However, the company posted a loss from operations of $10.7 million, and adjusted EBITDA was negative at $0.7 million. Full-year guidance predicts revenue between $328 million and $333 million with an adjusted loss per share of $1.10 to $1.12.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced its participation in major investor conferences. Management will present at the Stifel 2022 Healthcare Conference on November 16, 2022, at 11:30 a.m. ET, with a live audio webcast available on their website. Additionally, they will host investor meetings at the Canaccord Genuity Medtech Forum on November 17, 2022. AtriCure provides innovative technologies including the Isolator® Synergy™ Ablation System and AtriClip® for Afib treatment, affecting over 37 million people worldwide.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), announced it will release its third quarter 2022 financial results on November 1, 2022, at 4:30 p.m. Eastern Time. The company invites investors to join an audio webcast to discuss the results, accessible on their corporate website. AtriCure is known for its innovative technologies, such as the Isolator® Synergy™ Ablation System and AtriClip® Left Atrial Appendage Exclusion System, which are widely used for Afib treatment and related conditions.
AtriCure, Inc. (NASDAQ: ATRC) announced an investor education webcast scheduled for September 28, 2022, at 2:00 p.m. ET, focusing on Hybrid AF Therapy. The webcast will feature insights from management and leading experts, alongside an interactive Q&A session. Interested participants can register on the company’s website. AtriCure is recognized for its innovative solutions addressing atrial fibrillation (Afib), with products such as the Isolator® Synergy™ Ablation System and AtriClip® LAA Exclusion System. These technologies cater to a market affecting over 33 million people globally.
AtriCure, Inc. (NASDAQ: ATRC), a leading innovator in surgical treatments for atrial fibrillation (Afib), announced its participation in the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 1:30 p.m. Eastern Time. The event will be accessible via a live audio webcast on the company’s website. AtriCure specializes in innovative technologies for Afib treatment, with over 33 million people affected worldwide. Its FDA-approved Isolator® Synergy™ Ablation System leads the market in persistent Afib treatment.
AtriCure, Inc. (Nasdaq: ATRC) reported a strong second quarter of 2022 with revenues reaching $84.5 million, a growth of 18.4% compared to the previous year. U.S. sales rose by 18.6% to $71.3 million, driven by significant demand for products like the cryoSPHERE® probe and AtriClip® devices. However, the company recorded a loss from operations of $13.7 million with an adjusted EBITDA loss of $3.2 million. For 2022, AtriCure anticipates revenues between $323 million and $333 million, reflecting 18% to 21% growth over 2021.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib) and related conditions, has announced participation in two investor conferences. The management will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 10:00 a.m. ET. Additionally, they will engage in meetings at the 7th Annual Needham Virtual Med Tech & Diagnostics Conference on August 15, 2022. AtriCure is known for its innovative technologies, including the first FDA-approved device for persistent Afib treatment and widely used devices for left atrial appendage management.
AtriCure, a leader in surgical treatments for atrial fibrillation (Afib), will release its second quarter 2022 financial results on August 2, 2022. An audio webcast will be held at 4:30 p.m. Eastern Time to discuss these results, accessible via AtriCure's investor page. The Isolator® Synergy™ Ablation System, the first FDA-approved device for persistent Afib, and the widely used AtriClip® devices showcase the company's innovation in Afib management. With over 33 million Afib patients globally, AtriCure continues to address related healthcare challenges.
AtriCure announced the initiation of the HEAL-IST trial, the first patient was treated at University Hospital Brussels. This trial will assess the safety and effectiveness of AtriCure’s Isolator® Synergy™ Clamp for patients with Inappropriate Sinus Tachycardia, a condition that affects young adults with limited treatment options. The trial will involve 142 patients across 40 centers in the U.S. and Europe, focusing on achieving a heart rate of less than 90 bpm. The study aims to establish a new standard of care for this condition.